{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "7828638",
  "DateCompleted": {
    "Year": "1995",
    "Month": "02",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "06",
    "Day": "24"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0014-2999",
      "JournalIssue": {
        "Volume": "264",
        "Issue": "1",
        "PubDate": {
          "Year": "1994",
          "Month": "Oct",
          "Day": "13"
        }
      },
      "Title": "European journal of pharmacology",
      "ISOAbbreviation": "Eur J Pharmacol"
    },
    "ArticleTitle": "Antianxiety actions of Ca2+ channel antagonists with Vogel-type conflict test in rats.",
    "Pagination": {
      "StartPage": "107",
      "EndPage": "110",
      "MedlinePgn": "107-10"
    },
    "Abstract": {
      "AbstractText": [
        "We examined the effects of various derivatives of Ca2+ channel antagonists in a modified rat Vogel-type conflict model. Flunarizine (10 and 20 mg/kg), nicardipine (20 mg/kg), and verapamil (20 mg/kg), given as single i.p. injections, significantly increased punished lickings by 50-110%. Chronic administration of diltiazem, at 20 mg/kg i.p. for 8 days, a dose ineffective with a single i.p. injection, produced a significant anticonflict action. The possibility that Ca2+ channel antagonists have anxiolytic action should be considered."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology, School Nurse Training, Kyushu Women's Jr. College, Japan."
          }
        ],
        "LastName": "Matsumoto",
        "ForeName": "Y",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kataoka",
        "ForeName": "Y",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Watanabe",
        "ForeName": "Y",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Miyazaki",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Taniyama",
        "ForeName": "K",
        "Initials": "K"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Eur J Pharmacol",
    "NlmUniqueID": "1254354",
    "ISSNLinking": "0014-2999"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Calcium Channel Blockers"
    },
    {
      "RegistryNumber": "SY7Q814VUP",
      "NameOfSubstance": "Calcium"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "drug therapy",
        "physiopathology",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Behavior, Animal"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Calcium"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Calcium Channel Blockers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Electric Stimulation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Injections, Intraperitoneal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Wistar"
    }
  ]
}